Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:18:11 EDT Fri 21 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PHAR - PHARMING GROUP NV SPON ADS EACH REP 10 ORD SHS - https://www.pharmanetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHAR - Q0.18.57·8.670.58.5801-0.1899-2.24.235168.67  8.68  8.580111.35  6.6511:48:00Mar 2015 min RT 2¢

Recent Trades - Last 10 of 16
Time ETExPriceChangeVolume
11:48:00Q8.5801-0.1899100
11:45:42Q8.68-0.09128
11:45:42Q8.68-0.24531
11:35:25Q8.68-0.09500
11:35:24Q8.68-0.09500
11:35:23Q8.68-0.09100
11:35:23Q8.68-0.09300
11:35:23Q8.67-0.10500
09:47:48Q8.63-0.2957
09:46:08Q8.64-0.28557

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-20 02:00U:PHARNews ReleasePharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
2025-03-13 02:00U:PHARNews ReleasePharming Group reports fourth quarter and full year 2024 financial results and provides business update
2025-03-04 09:15U:PHARNews ReleasePharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
2025-02-28 02:00U:PHARNews ReleasePharming Group to participate in March investor conference
2025-02-27 02:00U:PHARNews ReleasePharming Group to report fourth quarter and full year 2024 financial results on March 13
2025-02-10 02:00U:PHARNews ReleasePharming Group to participate in February investor conference
2025-01-21 01:00U:PHARNews ReleasePharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
2024-12-15 13:45U:PHARNews ReleasePharming announces public cash offer to the shareholders of Abliva AB
2024-12-11 01:00U:PHARNews ReleasePharming announces positive topline data in pediatric clinical trial of leniolisib
2024-11-05 02:00U:PHARNews ReleasePharming Group to participate in November investor conference
2024-10-24 01:00U:PHARNews ReleasePharming Group reports third quarter 2024 financial results and provides business update
2024-10-10 02:00U:PHARNews ReleasePharming Group to report third quarter 2024 financial results on October 24
2024-10-10 01:00U:PHARNews ReleasePharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
2024-09-26 01:00U:PHARNews ReleasePharming announces marketing authorization in the U.K. for Joenja(TM) (leniolisib)
2024-09-04 01:00U:PHARNews ReleasePharming Group to participate in September investor conferences
2024-08-01 01:00U:PHARNews ReleasePharming Group reports second quarter and first half 2024 financial results and provides business update
2024-07-18 02:00U:PHARNews ReleasePharming Group to report second quarter and first half 2024 financial results on August 1
2024-06-03 02:00U:PHARNews ReleasePharming Group to participate in June investor conferences
2024-05-21 11:30U:PHARNews ReleasePharming Group reports on results of the 2024 Annual General Meeting of Shareholders
2024-05-20 02:00U:PHARNews ReleasePharming Group to participate in May investor conference